Literature DB >> 26985083

Interdisciplinary Systems-Based Intervention to Improve IV Hydration during Parenteral Administration of Acyclovir.

Lisa Dubrofsky1, Ryan S Kerzner2, Chloë Delaunay3, Camille Kolenda4, Jocelyne Pepin5, Blair C Schwartz6.   

Abstract

BACKGROUND: Intravenous (IV) hydration is considered a protective factor in reducing the incidence of acyclovir-induced nephrotoxicity. A systems-based review of cases of acyclovir-associated acute kidney injury can be used to examine institution-, care provider-, and task-related factors involved in administering the drug and can serve as a basis for developing a quality improvement intervention to achieve safer administration of acyclovir.
OBJECTIVES: To explore the effectiveness of the study institution's inter-disciplinary quality improvement intervention in increasing the dilution of acyclovir before IV administration.
METHODS: After conducting a systems-based review for intervention development, a retrospective analysis was undertaken to compare IV administration of acyclovir in the 6-month periods before and after implementation of the intervention. The study population was a sequential sample of all patients over 18 years of age who were seen in the emergency department or admitted to a ward and who received at least one IV dose of acyclovir at the study institution. The primary outcome was the volume in which each acyclovir dose was delivered. The secondary outcomes were the hourly rate of fluid administration, the frequency of an increase in hourly hydration rate, and the incidence of acute kidney injury.
RESULTS: Eighty-four patients (44 in the pre-intervention period and 40 in the post-intervention period) received IV acyclovir and had evaluable data for the primary outcome. The median volume in which the acyclovir dose was administered was significantly higher in the post-intervention group (250 mL versus 100 mL, p < 0.001).
CONCLUSIONS: In this study, an easily implemented intervention significantly increased the volume of IV fluid administered to patients receiving acyclovir. Adequately powered prospective studies are suggested to investigate the effectiveness of this intervention on the clinically relevant incidence of acyclovir-induced nephrotoxicity.

Entities:  

Keywords:  acute kidney insufficiency; acyclovir; medication errors; patient safety

Year:  2016        PMID: 26985083      PMCID: PMC4777587          DOI: 10.4212/cjhp.v69i1.1517

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN: 0008-4123


  18 in total

1.  Defining and classifying clinical indicators for quality improvement.

Authors:  Jan Mainz
Journal:  Int J Qual Health Care       Date:  2003-12       Impact factor: 2.038

2.  Understanding and responding to adverse events.

Authors:  Charles Vincent
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

Review 3.  Acyclovir: a decade later.

Authors:  R J Whitley; J W Gnann
Journal:  N Engl J Med       Date:  1992-09-10       Impact factor: 91.245

4.  A web-based tool for the Comprehensive Unit-based Safety Program (CUSP).

Authors:  Peter J Pronovost; Jay King; Christine G Holzmueller; Melinda Sawyer; Shauna Bivens; Michelle Michael; Kathy Haig; Lori Paine; Dana Moore; Marlene Miller
Journal:  Jt Comm J Qual Patient Saf       Date:  2006-03

Review 5.  Framework for analysing risk and safety in clinical medicine.

Authors:  C Vincent; S Taylor-Adams; N Stanhope
Journal:  BMJ       Date:  1998-04-11

6.  Human factors engineering design demonstrations can enlighten your RCA team.

Authors:  J Gosbee; T Anderson
Journal:  Qual Saf Health Care       Date:  2003-04

7.  Novel low-resource intervention reduces urinary catheter use and associated urinary tract infections: role of outcome measure bias?

Authors:  Blair Carl Schwartz; Charles Frenette; Todd C Lee; Laurence Green; Dev Jayaraman
Journal:  Am J Infect Control       Date:  2015-02-10       Impact factor: 2.918

Review 8.  Herpes simplex encephalitis: a review.

Authors:  R E Levitz
Journal:  Heart Lung       Date:  1998 May-Jun       Impact factor: 2.210

9.  Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans.

Authors:  O L Laskin; J A Longstreth; R Saral; P de Miranda; R Keeney; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

10.  Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.

Authors:  Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more
  5 in total

1.  Incidence, patterns, risk factors and clinical outcomes of intravenous acyclovir induced nephrotoxicity.

Authors:  Abdullah M Al-Alawi; Juhaina Salim Al-Maqbali; Maria Al-Adawi; Anan Al-Jabri; Henrik Falhammar
Journal:  Saudi Pharm J       Date:  2022-03-26       Impact factor: 4.562

Review 2.  Antiviral Agents for the Prevention and Treatment of Herpes Simplex Virus Type-1 Infection in Clinical Oncology: A Network Meta-Analysis.

Authors:  Farah Wasim Aribi Al-Zoobaee; Loo Yee Shen; Sajesh K Veettil; Divya Gopinath; Mari Kannan Maharajan; Rohit Kunnath Menon
Journal:  Int J Environ Res Public Health       Date:  2020-11-30       Impact factor: 3.390

Review 3.  Critical Review of Synthesis, Toxicology and Detection of Acyclovir.

Authors:  Yan-Ping Wei; Liang-Yuan Yao; Yi-Yong Wu; Xia Liu; Li-Hong Peng; Ya-Ling Tian; Jian-Hua Ding; Kang-Hua Li; Quan-Guo He
Journal:  Molecules       Date:  2021-10-29       Impact factor: 4.411

4.  Systemic Defenses to Prevent Intravenous Medication Errors in Hospitals: A Systematic Review.

Authors:  Sini Karoliina Kuitunen; Ilona Niittynen; Marja Airaksinen; Anna-Riia Holmström
Journal:  J Patient Saf       Date:  2021-12-01       Impact factor: 2.243

5.  Incidence and predictors of intravenous acyclovir-induced nephrotoxicity.

Authors:  Rasmus K B Richelsen; Signe B Jensen; Henrik Nielsen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-08-07       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.